* Agios Pharmaceuticals Inc AGIO.OQ reported a quarterly
adjusted loss of $2.42 per share for the quarter ended January
1, lower than the same quarter last year, when the company
reported EPS of $-1.64. The mean expectation of ten analysts
for the quarter was for earnings of $1.11 per share. Wall Street
expected results to range from $-1.85 to $12.42 per share.
* Revenue rose 21.2% to $8.96 million from a year ago;
analysts
expected $9.46 million.
* Agios Pharmaceuticals Inc's reported EPS for the quarter
was
$16.22.
* The company reported quarterly net income of $947.92
million.
* Agios Pharmaceuticals Inc shares had risen by 4.2% this
quarter and gained 107.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 209.9%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Agios
Pharmaceuticals Inc is $56.00
This summary was machine generated from LSEG data November 1 at
03:32 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 1.11 -2.42 Missed
Jun. 30 2024 -1.60 -1.69 Missed
Mar. 31 2024 -1.65 -1.45 Beat
Dec. 31 2023 -1.65 -1.72 Missed